<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">31643998</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK548688</ArticleId></ArticleIdList><Book><Publisher><PublisherName>National Institute of Diabetes and Digestive and Kidney Diseases</PublisherName><PublisherLocation>Bethesda (MD)</PublisherLocation></Publisher><BookTitle book="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</BookTitle><PubDate><Year>2012</Year></PubDate><BeginningDate><Year>2012</Year></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="livertox" part="Saxagliptin">Saxagliptin</ArticleTitle><Language>eng</Language><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText>Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other oral hypoglycemic agents. Saxagliptin is a relatively new medication and has yet to be implicated in causing clinically apparent liver injury.</AbstractText></Abstract><Sections><Section><SectionTitle book="livertox" part="Saxagliptin" sec="Saxagliptin.OVERVIEW">OVERVIEW</SectionTitle></Section><Section><SectionTitle book="livertox" part="Saxagliptin" sec="Saxagliptin.PRODUCT_INFORMATION">PRODUCT INFORMATION</SectionTitle></Section><Section><SectionTitle book="livertox" part="Saxagliptin" sec="Saxagliptin.CHEMICAL_FORMULA_AND_STRUCTU">CHEMICAL FORMULA AND STRUCTURE</SectionTitle></Section></Sections><ContributionDate><Year>2018</Year><Month>1</Month><Day>3</Day></ContributionDate></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31643998</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
